Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Car-BiRD Therapy for Newly Diagnosed Multiple Myeloma
NCT01559935Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2012
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Primary endpoint: Response to Car-BiRD Treatment at 116 weeks. Started Apr 2012; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01559935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01559935.